About Allen Biotechnology Co
Biology is a design problem. We treat it like one.
Founded by structural biologists and machine-learning researchers, Allen Biotechnology Co exists to shorten the distance between a scientific insight and a working therapeutic.
Our mission
Make rational biologic design the default, not the exception
Most therapeutic candidates still fail late, after years of investment, because early design choices weren't grounded in structure. We build the computational and experimental infrastructure that lets teams make those choices correctly the first time — de-risking programs before they reach the clinic.
What guides us
Principles over process
Evidence before elegance
A model is only as good as the wet-lab data that validates it. We test relentlessly.
Shared incentives
Partnerships are structured so our success and our collaborators' success are the same outcome.
Speed with rigor
We move quickly because our processes are disciplined, not despite it.
Our path
From a two-person lab to a full discovery platform
2018
Founded
Started in a shared lab space with a single structure-prediction model and one target.
2020
First platform partner
Signed our first co-development agreement and opened an automated screening facility.
2023
Clinic-ready candidate
Advanced our first internally discovered oncology candidate into IND-enabling studies.
2026
140+ team members
Now running 34 active programs across oncology, immunology, and rare disease.
Leadership
A team spanning structural biology and machine learning
Dr. Maya Allen
Co-founder & CEO — structural biology, ex-academic PI
Dr. Ravi Kapoor
Co-founder & CSO — computational protein design
Elena Farrow
VP, Process Development — biologics manufacturing
Dr. Sam Okoye
VP, Translational Science — clinical development
Interested in joining us?
We're hiring across computational biology, wet-lab science, and process development.